Search research articles
Contact Us
Filters
Showing results (471-480 of 529) with videos related to
Page
of 53
Sort By:
The American Journal of Cardiology
|
May 12, 2015
Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)
Steven M Bradley, Paul S Chan, Pamela M Hartigan, et al.
Circulation. Cardiovascular Quality and Outcomes
|
July 29, 2010
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
Bernard R Chaitman, Pamela M Hartigan, David C Booth, et al.
Journal of the American College of Cardiology
|
July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
David J Maron, William E Boden, John A Spertus, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 9, 2020
Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study
Hertzel C Gerstein, Eric E Smith, Chinthanie Ramasundarahettige, et al.
The American Journal of Cardiology
|
July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology
|
October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
David J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
American Heart Journal
|
September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
CJC Open
|
December 11, 2020
The Canadian Alliance for Healthy Hearts and Minds: How Well Does It Reflect the Canadian Population?
Ruth E Hall, Natasa Tusevljak, C Fangyun Wu, et al.
American Heart Journal
|
June 20, 2006
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
William E Boden, Robert A O'rourke, Koon K Teo, et al.
Page
of 53
Search research articles
Search
Showing results (471-480 of 529) with videos related to
Sort By:
Page
of 53
The American Journal of Cardiology
|
May 12, 2015
Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)
Steven M Bradley, Paul S Chan, Pamela M Hartigan, et al.
Circulation. Cardiovascular Quality and Outcomes
|
July 29, 2010
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
Bernard R Chaitman, Pamela M Hartigan, David C Booth, et al.
Journal of the American College of Cardiology
|
July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
David J Maron, William E Boden, John A Spertus, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 9, 2020
Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study
Hertzel C Gerstein, Eric E Smith, Chinthanie Ramasundarahettige, et al.
The American Journal of Cardiology
|
July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology
|
October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
David J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
American Heart Journal
|
September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
CJC Open
|
December 11, 2020
The Canadian Alliance for Healthy Hearts and Minds: How Well Does It Reflect the Canadian Population?
Ruth E Hall, Natasa Tusevljak, C Fangyun Wu, et al.
American Heart Journal
|
June 20, 2006
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
William E Boden, Robert A O'rourke, Koon K Teo, et al.
Page
of 53